Avacta Group PLC - Wetherby-based biotherapeutics firm - Says results for its first Affimer-based Covid-19 test strips show the strips detect SARS-COV-2 spike protein in samples at concentrations within the clinical range found in saliva of patients with Covid-19. Work is now ongoing to refine the test strip design, optimise its performance and get the best detection limit possible for the final product. Following optimisation of the test, the design will then be transferred to manufacturing partners in the UK.
Current stock price: 136.40 pence
Year-to-date change: up nearly eight-fold
By Ife Taiwo; ifetaiwo@alliancenews.com
Copyright 2020 Alliance News Limited. All Rights Reserved.
Avacta Group (AVCT)